Haloperidol, a sigma receptor 1 antagonist, promotes ferroptosis in hepatocellular carcinoma cells

Biochemical and Biophysical Research Communications

Volumn 491, Issue 4, 2017, Pages 919-925

  Bai, Tao ^a   Wang, Shuai ^a   Zhao, Yipu ^a   Zhu, Rongtao ^a   Wang, Weijie ^a   Sun, Yuling ^a  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

Author keywords

Ferroptosis; Haloperidol; Hepatocellular carcinoma; Sorafenib

Indexed keywords

ANTINEOPLASTIC AGENT; ERASTIN; FERROUS ION; GLUTATHIONE; HALOPERIDOL; SIGMA 1 OPIATE RECEPTOR; SORAFENIB; UNCLASSIFIED DRUG; CARBANILAMIDE DERIVATIVE; IRON; NICOTINAMIDE; PIPERAZINE DERIVATIVE; SIGMA OPIATE RECEPTOR; SIGMA-1 RECEPTOR;

ARTICLE; CARCINOMA CELL; CELL DEATH; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; FERROPTOSIS; HUMAN; HUMAN CELL; IRON STORAGE; LIPID PEROXIDATION; LIVER CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; UPREGULATION; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECTS; GENETICS; LIVER NEOPLASMS; METABOLISM; PATHOLOGY; STRUCTURE ACTIVITY RELATION; TUMOR CELL CULTURE;

APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HALOPERIDOL; HUMANS; IRON; LIVER NEOPLASMS; NIACINAMIDE; PHENYLUREA COMPOUNDS; PIPERAZINES; RECEPTORS, SIGMA; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 85026478644     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2017.07.136     Document Type: Article

References (42)

1. Dixon, S.J., Lemberg, K.M., Lamprecht, M.R., Skouta, R., Zaitsev, E.M., Gleason, C.E., Patel, D.N., Bauer, A.J., Cantley, A.M., Yang, W.S., Morrison, B. 3rd, Stockwell, B.R., Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 149 (2012), 1060–1072.
2. Yang, W.S., SriRamaratnam, R., Welsch, M.E., Shimada, K., Skouta, R., Viswanathan, V.S., Cheah, J.H., Clemons, P.A., Shamji, A.F., Clish, C.B., Brown, L.M., Girotti, A.W., Cornish, V.W., Schreiber, S.L., Stockwell, B.R., Regulation of ferroptotic cancer cell death by GPX4. Cell 156 (2014), 317–331.
3. Eling, N., Reuter, L., Hazin, J., Hamacher-Brady, A., Brady, N.R., Identification of artesunate as a specific activator of ferroptosis in pancreatic cancer cells. Oncoscience 2 (2015), 517–532.
4. Louandre, C., Marcq, I., Bouhlal, H., Lachaier, E., Godin, C., Saidak, Z., Francois, C., Chatelain, D., Debuysscher, V., Barbare, J.C., Chauffert, B., Galmiche, A., The retinoblastoma (Rb) protein regulates ferroptosis induced by sorafenib in human hepatocellular carcinoma cells. Cancer Lett. 356 (2015), 971–977.
5. Sun, X., Ou, Z., Chen, R., Niu, X., Chen, D., Kang, R., Tang, D., Activation of the p62-Keap1-NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cells. Hepatology 63 (2016), 173–184.
6. Kwon, M.Y., Park, E., Lee, S.J., Chung, S.W., Heme oxygenase-1 accelerates erastin-induced ferroptotic cell death. Oncotarget 6 (2015), 24393–24403.
7. Jiang, L., Kon, N., Li, T., Wang, S.J., Su, T., Hibshoosh, H., Baer, R., Gu, W., Ferroptosis as a p53-mediated activity during tumour suppression. Nature 520 (2015), 57–62.
8. Collina, S., Gaggeri, R., Marra, A., Bassi, A., Negrinotti, S., Negri, F., Rossi, D., Sigma receptor modulators: a patent review. Expert Opin. Ther. Pat. 23 (2013), 597–613.
9. Hayashi, T., Su, T.P., Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca(2+) signaling and cell survival. Cell 131 (2007), 596–610.
10. Kourrich, S., Hayashi, T., Chuang, J.Y., Tsai, S.Y., Su, T.P., Bonci, A., Dynamic interaction between sigma-1 receptor and Kv1.2 shapes neuronal and behavioral responses to cocaine. Cell 152 (2013), 236–247.
11. Tsai, S.Y., Chuang, J.Y., Tsai, M.S., Wang, X.F., Xi, Z.X., Sigma-1 Receptor Mediates Cocaine-induced Transcriptional Regulation by Recruiting Chromatin-remodeling Factors at the Nuclear Envelope, vol. 112, 2015, E6562–E6570.
12. Hosszu, A., Antal, Z., Lenart, L., Hodrea, J., Koszegi, S., Balogh, D.B., Banki, N.F., Wagner, L., Denes, A., Hamar, P., Degrell, P., Vannay, A., Szabo, A.J., Fekete, A., sigma1-Receptor agonism protects against renal ischemia-reperfusion injury. J. Am. Soc. Nephrol. 28 (2017), 152–165.
13. Narayanan, S., Bhat, R., Mesangeau, C., Poupaert, J.H., McCurdy, C.R., Early development of sigma-receptor ligands. Future Med. Chem. 3 (2011), 79–94.
14. Hayashi, T., Fujimoto, M., Detergent-resistant microdomains determine the localization of sigma-1 receptors to the endoplasmic reticulum-mitochondria junction. Mol. Pharmacol. 77 (2010), 517–528.
15. Pal, A., Fontanilla, D., Gopalakrishnan, A., Chae, Y.K., Markley, J.L., Ruoho, A.E., The sigma-1 receptor protects against cellular oxidative stress and activates antioxidant response elements. Eur. J. Pharmacol. 682 (2012), 12–20.
16. Wang, J., Shanmugam, A., Markand, S., Zorrilla, E., Ganapathy, V., Smith, S.B., Sigma 1 receptor regulates the oxidative stress response in primary retinal Muller glial cells via NRF2 signaling and system xc(-), the Na(+)-independent glutamate-cystine exchanger. Free Radic. Biol. Med. 86 (2015), 25–36.
17. Rousseaux, C.G., Greene, S.F., Sigma receptors [sigmaRs]: biology in normal and diseased states. J. Recept Signal Transduct. Res., 2015, 1–62.
18. Lachaier, E., Louandre, C., Godin, C., Saidak, Z., Baert, M., Diouf, M., Chauffert, B., Galmiche, A., Sorafenib induces ferroptosis in human cancer cell lines originating from different solid tumors. Anticancer Res. 34 (2014), 6417–6422.
19. Dixon, S.J., Patel, D.N., Welsch, M., Skouta, R., Lee, E.D., Hayano, M., Thomas, A.G., Gleason, C.E., Tatonetti, N.P., Slusher, B.S., Stockwell, B.R., Pharmacological Inhibition of Cystine-glutamate Exchange Induces Endoplasmic Reticulum Stress and Ferroptosis, vol. 3, 2014, e02523.
20. Louandre, C., Ezzoukhry, Z., Godin, C., Barbare, J.C., Maziere, J.C., Chauffert, B., Galmiche, A., Iron-dependent cell death of hepatocellular carcinoma cells exposed to sorafenib. Int. J. Cancer 133 (2013), 1732–1742.
21. Galluzzi, L., Bravo-San Pedro, J.M., Vitale, I., Aaronson, S.A., Abrams, J.M., Adam, D., Alnemri, E.S., Altucci, L., Andrews, D., Annicchiarico-Petruzzelli, M., Baehrecke, E.H., Bazan, N.G., Bertrand, M.J., Bianchi, K., Blagosklonny, M.V., Blomgren, K., Borner, C., Bredesen, D.E., Brenner, C., Campanella, M., Candi, E., Cecconi, F., Chan, F.K., Chandel, N.S., Cheng, E.H., Chipuk, J.E., Cidlowski, J.A., Ciechanover, A., Dawson, T.M., Dawson, V.L., De Laurenzi, V., De Maria, R., Debatin, K.M., Di Daniele, N., Dixit, V.M., Dynlacht, B.D., El-Deiry, W.S., Fimia, G.M., Flavell, R.A., Fulda, S., Garrido, C., Gougeon, M.L., Green, D.R., Gronemeyer, H., Hajnoczky, G., Hardwick, J.M., Hengartner, M.O., Ichijo, H., Joseph, B., Jost, P.J., Kaufmann, T., Kepp, O., Klionsky, D.J., Knight, R.A., Kumar, S., Lemasters, J.J., Levine, B., Linkermann, A., Lipton, S.A., Lockshin, R.A., Lopez-Otin, C., Lugli, E., Madeo, F., Malorni, W., Marine, J.C., Martin, S.J., Martinou, J.C., Medema, J.P., Meier, P., Melino, S., Mizushima, N., Moll, U., Munoz-Pinedo, C., Nunez, G., Oberst, A., Panaretakis, T., Penninger, J.M., Peter, M.E., Piacentini, M., Pinton, P., Prehn, J.H., Puthalakath, H., Rabinovich, G.A., Ravichandran, K.S., Rizzuto, R., Rodrigues, C.M., Rubinsztein, D.C., Rudel, T., Shi, Y., Simon, H.U., Stockwell, B.R., Szabadkai, G., Tait, S.W., Tang, H.L., Tavernarakis, N., Tsujimoto, Y., Vanden Berghe, T., Vandenabeele, P., Villunger, A., Wagner, E.F., et al. Essential versus accessory aspects of cell death: recommendations of the NCCD 2015. Cell Death Differ. 22 (2015), 58–73.
22. Xie, Y., Hou, W., Song, X., Yu, Y., Huang, J., Sun, X., Kang, R., Tang, D., Ferroptosis: process and function. Cell Death Differ. 23 (2016), 369–379.
23. Jemal, A., Bray, F., Center, M.M., Ferlay, J., Ward, E., Forman, D., Global cancer statistics. CA Cancer J. Clin. 61 (2011), 69–90.
24. Llovet, J.M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.F., de Oliveira, A.C., Santoro, A., Raoul, J.L., Forner, A., Schwartz, M., Porta, C., Zeuzem, S., Bolondi, L., Greten, T.F., Galle, P.R., Seitz, J.F., Borbath, I., Haussinger, D., Giannaris, T., Shan, M., Moscovici, M., Voliotis, D., Bruix, J., Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359 (2008), 378–390.
25. Abou-Alfa, G.K., Schwartz, L., Ricci, S., Amadori, D., Santoro, A., Figer, A., De Greve, J., Douillard, J.Y., Lathia, C., Schwartz, B., Taylor, I., Moscovici, M., Saltz, L.B., Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J. Clin. Oncol. 24 (2006), 4293–4300.
26. Zhai, B., Sun, X.Y., Mechanisms of resistance to sorafenib and the corresponding strategies in hepatocellular carcinoma. World J. Hepatol. 5 (2013), 345–352.
27. Llovet, J.M., Bruix, J., Molecular targeted therapies in hepatocellular carcinoma. Hepatology 48 (2008), 1312–1327.
28. Villanueva, A., Llovet, J.M., Targeted therapies for hepatocellular carcinoma. Gastroenterology 140 (2011), 1410–1426.
29. Liu, L., Cao, Y., Chen, C., Zhang, X., McNabola, A., Wilkie, D., Wilhelm, S., Lynch, M., Carter, C., Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res. 66 (2006), 11851–11858.
30. Wilhelm, S., Carter, C., Lynch, M., Lowinger, T., Dumas, J., Smith, R.A., Schwartz, B., Simantov, R., Kelley, S., Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat. Rev. Drug Discov. 5 (2006), 835–844.
31. Sun, X., Niu, X., Chen, R., He, W., Chen, D., Kang, R., Tang, D., Metallothionein-1G facilitates sorafenib resistance through inhibition of ferroptosis. Hepatology 64 (2016), 488–500.
32. Coriat, R., Nicco, C., Chereau, C., Mir, O., Alexandre, J., Ropert, S., Weill, B., Chaussade, S., Goldwasser, F., Batteux, F., Sorafenib-induced hepatocellular carcinoma cell death depends on reactive oxygen species production in vitro and in vivo. Mol. Cancer Ther. 11 (2012), 2284–2293.
33. Schetz, J.A., Perez, E., Liu, R., Chen, S., Lee, I., Simpkins, J.W., A prototypical Sigma-1 receptor antagonist protects against brain ischemia. Brain Res. 1181 (2007), 1–9.
34. Happy, M., Dejoie, J., Zajac, C.K., Cortez, B., Chakraborty, K., Aderemi, J., Sauane, M., Sigma 1 Receptor antagonist potentiates the anti-cancer effect of p53 by regulating ER stress, ROS production, Bax levels, and caspase-3 activation. Biochem. Biophys. Res. Commun. 456 (2015), 683–688.
35. Spruce, B.A., Campbell, L.A., McTavish, N., Cooper, M.A., Appleyard, M.V., O'Neill, M., Howie, J., Samson, J., Watt, S., Murray, K., McLean, D., Leslie, N.R., Safrany, S.T., Ferguson, M.J., Peters, J.A., Prescott, A.R., Box, G., Hayes, A., Nutley, B., Raynaud, F., Downes, C.P., Lambert, J.J., Thompson, A.M., Eccles, S., Small molecule antagonists of the sigma-1 receptor cause selective release of the death program in tumor and self-reliant cells and inhibit tumor growth in vitro and in vivo. Cancer Res. 64 (2004), 4875–4886.
36. van Waarde, A., Rybczynska, A.A., Ramakrishnan, N., Ishiwata, K., Elsinga, P.H., Dierckx, R.A., Sigma receptors in oncology: therapeutic and diagnostic applications of sigma ligands. Curr. Pharm. Des. 16 (2010), 3519–3537.
37. van Waarde, A., Rybczynska, A.A., Ramakrishnan, N.K., Ishiwata, K., Elsinga, P.H., Dierckx, R.A., Potential applications for sigma receptor ligands in cancer diagnosis and therapy. Biochim. Biophys. Acta 1848 (2015), 2703–2714.
38. Carlson, B.A., Tobe, R., Yefremova, E., Tsuji, P.A., Hoffmann, V.J., Schweizer, U., Gladyshev, V.N., Hatfield, D.L., Conrad, M., Glutathione peroxidase 4 and vitamin E cooperatively prevent hepatocellular degeneration. Redox Biol. 9 (2016), 22–31.
39. Friedmann Angeli, J.P., Schneider, M., Proneth, B., Tyurina, Y.Y., Tyurin, V.A., Hammond, V.J., Herbach, N., Aichler, M., Walch, A., Eggenhofer, E., Basavarajappa, D., Radmark, O., Kobayashi, S., Seibt, T., Beck, H., Neff, F., Esposito, I., Wanke, R., Forster, H., Yefremova, O., Heinrichmeyer, M., Bornkamm, G.W., Geissler, E.K., Thomas, S.B., Stockwell, B.R., O'Donnell, V.B., Kagan, V.E., Schick, J.A., Conrad, M., Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice. Nat. Cell Biol. 16 (2014), 1180–1191.
40. Yu, H., Guo, P., Xie, X., Wang, Y., Chen, G., Ferroptosis, a new form of cell death, and its relationships with tumourous diseases. J. Cell Mol. Med. 21:4 (2017), 648–657.
41. Wu, D., Chen, L., Ferroptosis: a novel cell death form will be a promising therapy target for diseases. Acta Biochim. Biophys. Sin. (Shanghai) 47 (2015), 857–859.
42. Xie, Y., Song, X., Sun, X., Huang, J., Zhong, M., Lotze, M.T., Zeh, H.J. 3rd, Kang, R., Tang, D., Identification of baicalein as a ferroptosis inhibitor by natural product library screening. Biochem. Biophys. Res. Commun. 473 (2016), 775–780.